Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Alpha-dystroglycan, the usual suspect?

Andrea Brancaccio1

  • 1Istituto di Chimica del Riconoscimento Molecolare, CNR c/o, Istituto di Biochimica e Biochimica Clinica, Università Cattolica del Sacro Cuore, Largo Francesco Vito n.1, 00168 Roma, Italy. andrea.brancaccio@icrm.cnr.it

Neuromuscular Disorders : NMD
|November 18, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multi-method validation of the new computerized test of fluid intelligence MatriKS.

Behavior research methods·2026
Same author

Error patterns on a computerized version of Raven's progressive matrices in specific learning disorders.

Frontiers in psychology·2026
Same author

Generation of rule-based matrices with the matRiks package: a tutorial.

Frontiers in psychology·2026
Same author

Engineered GO-Based Hydrogels for Controlled Hyaluronic Acid Release in Knee Osteoarthritis Treatment.

Polymers·2026
Same author

Effect of Active and Assisted Living technologies on psychosocial well-being in older adults: systematic review.

Frontiers in public health·2026
Same author

α-Dystroglycan at the ECM-Cell crossroad: emerging functions of its N-terminal domain.

Matrix biology : journal of the International Society for Matrix Biology·2025
Same journal

Severe dilated cardiomyopathy in females with dystrophinopathy : a case series of nine patients.

Neuromuscular disorders : NMD·2026
Same journal

A portrait of facioscapulohumeral muscular dystrophy through history: past milestones and future challenges on the road to understanding and treatment.

Neuromuscular disorders : NMD·2026
Same journal

Systematic review of outcome measures in facioscapulohumeral dystrophy (FSHD): validated, usable, and feasible tools for assessing function, performance, and strength.

Neuromuscular disorders : NMD·2026
Same journal

Longitudinal functional trajectories in Duchenne muscular dystrophy: outcome-specific patterns from a registry-based modelling study.

Neuromuscular disorders : NMD·2026
Same journal

HACD1-related congenital myopathy skeletal muscle MRI findings in a Brazilian cohort.

Neuromuscular disorders : NMD·2026
Same journal

Sensory abnormalities and entrapment neuropathies identified by nerve conduction studies in patients with amyotrophic lateral sclerosis.

Neuromuscular disorders : NMD·2026
See all related articles

Genetic defects in glycosyltransferases can cause congenital muscular dystrophies by affecting alpha-dystroglycan (alpha-DG) glycosylation. This hypoglycosylation is linked to muscle weakness and sarcolemmal instability in secondary dystroglycanopathies.

Area of Science:

  • Biochemistry
  • Genetics
  • Molecular Biology

Background:

  • Congenital muscular dystrophies (CMDs) are often linked to genetic defects in glycosyltransferases.
  • These enzymes target the alpha subunit of the dystroglycan (DG) complex, crucial for sarcolemmal stability.
  • Abnormal glycosylation of alpha-DG (hypoglycosylation) is implicated in CMDs, affecting its binding to extracellular matrix components.

Purpose of the Study:

  • To explore the role of alpha-dystroglycan (alpha-DG) glycosylation in congenital muscular dystrophies.
  • To investigate the potential for primary dystroglycanopathies arising from mutations in the DG gene itself.
  • To understand the functional significance of altered alpha-DG glycosylation states and compensatory mechanisms.

Main Methods:

  • The study reviews existing evidence and proposes further research directions.

Related Experiment Videos

  • It focuses on the molecular mechanisms linking glycosyltransferases, alpha-DG, and muscle pathology.
  • Analysis of genetic mutations and their impact on protein function is central.

    • Main Results:

    • Hypoglycosylation of alpha-DG is a key molecular event in many CMDs, termed 'secondary dystroglycanopathies'.
    • This alteration compromises the binding of alpha-DG to laminin, disrupting the basement membrane-cytoskeleton linkage.
    • This leads to sarcolemmal instability, myofiber damage, and congenital muscle weakness.

    Conclusions:

    • Further research is needed to clarify the role of DG gene mutations in primary dystroglycanopathies.
    • The pathological impact of both hypo- and hyperglycosylated alpha-DG requires detailed investigation.
    • The compensatory roles of related glycosyltransferases in alpha-DG glycosylation warrant further study.